Protease inhibitors could be highly effective against SARS-CoV-2
Researchers reveal the main protease (Mpro) of SARS-CoV-2 is highly sensitive to disruption, therefore Mpro inhibitors could be a potential COVID-19 therapeutic.
List view / Grid view
Researchers reveal the main protease (Mpro) of SARS-CoV-2 is highly sensitive to disruption, therefore Mpro inhibitors could be a potential COVID-19 therapeutic.
Researchers used computational tools to identify regions of the SARS-CoV-2 virus that could potentially provide a safe and long-term immune response.
The team found microglia and CD8 T cells were vital to protecting neurons from vesicular stomatitis virus (VSV) infection and suggest loss of taste and smell in COVID-19 could be due to a certain mechanism of infection.
Pre-clinical testing of the COVIDTRAP™ (STI-4398) protein and STI-1499 antibody reveal they can inhibit SARS-CoV-2 from infecting cells.
Arsalan Azimi explains why inhibiting TMPRSS2 with clinically proven protease blockers could work as a therapeutic strategy against COVID-19.
Sarah Ahmed explores how environmental factors may be causing the disparity in numbers of cases between different countries.
Amid the rush to develop an effective vaccine against COVID-19, antibody therapy has become a major strategy to ameliorate and treat cases of severe disease. Armed with the capacity to neutralise pathogens and orchestrate the immune system, promising antibody candidates for multiple viral indications, including HIV, continue to emerge. Technology…
Sheraz Gul explores current research developments to help treat and tackle the spread of COVID-19.
Exploring large databases and selecting compounds of interest can be extremely time-consuming for researchers. Here, Sacha Javor, Horst Flotow and Jingwen Shi discuss a novel chemoinformatics approach for drug discovery.
Mass spectrometry revealed biomarkers that could be used as drug targets for developing novel therapeutics or to predict whether a patient with COVID-19 will become severely ill.
Researchers found there is a gradient of SARS-CoV-2 infectivity down the airway and that the severe pneumonia symptoms may be caused by aspiration of oral contents into the lungs.
Researchers in the US describe how they utilised previously published scientific literature to guide the design of their potential COVID-19 vaccine.
Researchers develop a knock-in mouse expressing human angiotensin-converting enzyme 2 (hACE2) to model SARS-CoV-2 infection for research and therapeutic or vaccine testing.
A new suggestion has highlighted that the available pharmacologically-established existing medicines should be used to combat COVID-19.
Collaboration between scientists, illustrators and simulators has culminated in highly detailed three-dimensional (3D) models of SARS-CoV-2.